- Pamidronate disodium
- Zoledronic Acid
- Denosumab
- Cyclosporin
- Risedronate
- Somatropin
The Osteogenesis Imperfecta (OI) Treatment Market size was valued at USD 743.9 million in 2023 and is poised to grow at a 3.5% CAGR from 2024 to 2030. Osteogenesis Imperfecta, also known as brittle bone disease, is a rare genetic disorder characterized by fragile bones that break easily. The growing awareness of rare diseases and advancements in genetic testing have significantly contributed to the market's growth. Moreover, the increasing prevalence of osteogenesis imperfecta, estimated at 1 in 10,000 to 20,000 births worldwide, has resulted in a faster adoption of novel treatment approaches. The COVID-19 pandemic had a mixed impact on the osteogenesis imperfecta treatment market. While it initially disrupted healthcare services and clinical trials, it also accelerated the adoption of telemedicine and remote patient monitoring, benefiting those with rare diseases like osteogenesis imperfecta. The market has seen a trend towards personalized medicine, with researchers focusing on developing targeted therapies based on specific genetic mutations causing osteogenesis imperfecta.
For instance, in 2022, a promising gene therapy approach using CRISPR-Cas9 technology showed potential in preclinical studies for treating certain types of osteogenesis imperfecta. Government initiatives and increased funding for rare disease research have been pivotal in driving market growth. For example, the European Joint Programme on Rare Diseases (EJP RD) has been instrumental in coordinating research efforts and improving diagnosis and treatment for rare conditions like osteogenesis imperfecta. Furthermore, patient advocacy groups such as the Osteogenesis Imperfecta Foundation have played a crucial role in raising awareness and supporting research initiatives. However, the high cost of treatment, particularly for advanced therapies and surgical interventions, remains a significant barrier to market growth. Additionally, the limited patient pool for clinical trials and the challenges in developing treatments for a genetically diverse condition like osteogenesis imperfecta pose obstacles to rapid advancements. Ongoing research into novel drug delivery systems and the potential of regenerative medicine offer promising opportunities for market players. The increasing focus on improving the quality of life for osteogenesis imperfecta patients, beyond just fracture prevention, is expected to drive innovation in supportive care and rehabilitation technologies.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The osteogenesis imperfecta treatment market is primarily driven by the increasing diagnosis rates due to improved genetic testing capabilities and growing awareness among healthcare professionals. The development of novel therapies, particularly in the realm of gene therapy and targeted molecular approaches, has sparked considerable interest and investment in the field. Moreover, the rising demand for multidisciplinary care approaches, combining medical, surgical, and rehabilitative interventions, has expanded the market landscape. The prevalence of osteogenesis imperfecta, while rare, presents a consistent need for effective treatments across all age groups, from infancy to adulthood. This has led to a diversification of treatment options, catering to different severities and types of osteogenesis imperfecta. The market has also seen a shift towards patient-centric care models, emphasizing quality-of-life improvements alongside fracture prevention. However, challenges persist. The need for lifelong management presents economic hurdles for patients and healthcare systems alike. Despite a few persisting challenges in terms of treatment accessibility, especially in developing regions where specialized care may be limited, the ongoing research into bone-strengthening agents, innovative surgical techniques, and potential curative approaches continue to drive market growth and offer hope for improved outcomes in osteogenesis imperfecta patients.
The Osteogenesis Imperfecta (OI) Treatment Market was valued at USD 743.9 million in 2023 and is expected to grow at a 3.5% CAGR from 2024 to 2030.
Mereo BioPharma Group plc, Bone Therapeutics, Amgen Inc., Novartis AG, and Eli Lilly and Company are some of the key players in the osteogenesis imperfecta treatment market.
Increasing diagnosis rates, advancements in genetic testing, development of novel therapies, and growing awareness of rare diseases are some of the factors predicted to propel the growth of the osteogenesis imperfecta treatment market.
North America is expected to dominate the osteogenesis imperfecta treatment market due to its advanced healthcare infrastructure, high healthcare spending, and strong focus on rare disease research.
High treatment costs, limited patient pool for clinical trials, and challenges in developing treatments for a genetically diverse condition are some factors expected to limit the growth of the osteogenesis imperfecta treatment market.
1.Executive Summary |
2.Global Osteogenesis Imperfecta (OI) Treatment Market Introduction |
2.1.Global Osteogenesis Imperfecta (OI) Treatment Market - Taxonomy |
2.2.Global Osteogenesis Imperfecta (OI) Treatment Market - Definitions |
2.2.1.Type |
2.2.2.Route Administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Osteogenesis Imperfecta (OI) Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Osteogenesis Imperfecta (OI) Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Osteogenesis Imperfecta (OI) Treatment Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Pamidronate disodium |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Zoledronic Acid |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Denosumab |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Cyclosporin |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Risedronate |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Somatropin |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Osteogenesis Imperfecta (OI) Treatment Market By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Injectable |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Osteogenesis Imperfecta (OI) Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online pharmacies. |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Osteogenesis Imperfecta (OI) Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Osteogenesis Imperfecta (OI) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Pamidronate disodium |
9.1.2.Zoledronic Acid |
9.1.3.Denosumab |
9.1.4.Cyclosporin |
9.1.5.Risedronate |
9.1.6.Somatropin |
9.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Injectable |
9.2.3.Others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital pharmacies |
9.3.2.Retail pharmacies |
9.3.3.Online pharmacies. |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Osteogenesis Imperfecta (OI) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Pamidronate disodium |
10.1.2.Zoledronic Acid |
10.1.3.Denosumab |
10.1.4.Cyclosporin |
10.1.5.Risedronate |
10.1.6.Somatropin |
10.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Injectable |
10.2.3.Others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital pharmacies |
10.3.2.Retail pharmacies |
10.3.3.Online pharmacies. |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Osteogenesis Imperfecta (OI) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Pamidronate disodium |
11.1.2.Zoledronic Acid |
11.1.3.Denosumab |
11.1.4.Cyclosporin |
11.1.5.Risedronate |
11.1.6.Somatropin |
11.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Injectable |
11.2.3.Others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital pharmacies |
11.3.2.Retail pharmacies |
11.3.3.Online pharmacies. |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Osteogenesis Imperfecta (OI) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Pamidronate disodium |
12.1.2.Zoledronic Acid |
12.1.3.Denosumab |
12.1.4.Cyclosporin |
12.1.5.Risedronate |
12.1.6.Somatropin |
12.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Injectable |
12.2.3.Others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital pharmacies |
12.3.2.Retail pharmacies |
12.3.3.Online pharmacies. |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Osteogenesis Imperfecta (OI) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Pamidronate disodium |
13.1.2.Zoledronic Acid |
13.1.3.Denosumab |
13.1.4.Cyclosporin |
13.1.5.Risedronate |
13.1.6.Somatropin |
13.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Injectable |
13.2.3.Others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital pharmacies |
13.3.2.Retail pharmacies |
13.3.3.Online pharmacies. |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Mereo BioPharma Group plc |
14.2.2.Bone Therapeutics |
14.2.3.Amgen Inc. |
14.2.4.Novartis AG |
14.2.5.Eli Lilly and Company |
14.2.6.Regeneron Pharmaceuticals, Inc. |
14.2.7.Alexion Pharmaceuticals, Inc. |
14.2.8.BioMarin Pharmaceutical Inc. |
14.2.9.Ultragenyx Pharmaceutical Inc. |
14.2.10.Pluristem Therapeutics Inc. |
14.2.11.CELGENE CORPORATION |
15. Research Methodology |
16. Appendix and Abbreviations |